资讯
After decades of racing to the bottom on pricing, a revolution is coming to the U.S. generics market, writes Yaral Pharma CEO ...
Advocacy for alternatives to animal testing in clinical research is pushing the industry away from animal-based endotoxin ...
Experts at Faegre Drinker offer life sciences business planning and risk mitigation strategies to consider in response to ...
Modern drug development approaches that integrate functional plans with larger business goals are needed for success in early ...
Vivani Medical is developing GLP-1 subdermal implants that aim to provide a consistent therapeutic dose for six months, and ...
In the 1980s, Lisa Conte was a biopharmaceutical venture capitalist. But she also was an aspiring entrepreneur, having a little business on the side called Wild Woods, which imported wood and ...
It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At the time, Anzalone was working as CEO of the Bennet Group, a private equity firm in Washington, D.C ...
Mike Fuller & Kim Kennedy Biotechnology companies are in an exceptionally competitive field, with multiple companies competing against each other for a chance to market similar innovative therapeutics ...
For people living with schizophrenia, the current drug treatment landscape is filled with cracks, crevices, and canyons that prevent a majority of patients from reaching anything close to a normal ...
Katie Dahler & Justin Hoss Is the bloom off the rose when it comes to investing in digital technology in the life sciences sector? It’s not, but it might not be blooming as fast as originally thought.
With six consecutive years of profitability (ahem, soon to be seven) and a market cap of nearly $13 billion, Genmab A/S represents one of Europe’s brightest biotech triumphs. But such wasn’t always ...
Funding for life science startups seeking to raise capital has been tight for the past four years. While there was optimism that 2025 may change the tide, we have not yet seen an ease in the flow of ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果